This study focused on the short-term efficacy of anti-VEGF therapy in macular edema patients by evaluating changes in central retinal thickness (CST) and best-corrected visual acuity (BCVA) within 24 h before and after treatment. This evidence concerns the gene VEGFA and macular retinal edema.